Taxol was administered to 25 patients with progressive ovarian cancer who had failed three or more lines of chemotherapy. A response rate of 27% was noted in 22 evaluable patients (5 partial responders; 1 complete responder). Median duration of response was only eight weeks. The impact of Taxol's use in this disease awaits the result of trials in which it is administered as first line therapy.